Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SANGAMO THERAPEUTICS, INC Director's Dealing 2018

Jan 5, 2018

33659_dirs_2018-01-04_c3e6ce6c-b2b1-46e2-8ef3-7cd8935b041b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SANGAMO THERAPEUTICS, INC (SGMO)
CIK: 0001001233
Period of Report: 2018-01-02

Reporting Person: Herberts Curt A. III (Sr.VP & Chief Business Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-01-02 Common Stock M 782 $9.41 Acquired 13015 Direct
2018-01-02 Common Stock M 209 $8.87 Acquired 13224 Direct
2018-01-02 Common Stock S 6974 $16.35 Disposed 6250 Direct
2018-01-03 Common Stock M 8026 $12.12 Acquired 14276 Direct
2018-01-03 Common Stock S 8026 $18.05 Disposed 6250 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-01-02 Stock Option (Right to Buy) $9.41 M 782 Disposed 2025-12-07 Common Stock (782) Direct
2018-01-02 Stock Option (Right to Buy) $8.87 M 209 Disposed 2025-07-26 Common Stock (209) Direct
2018-01-03 Stock Option (Right to Buy) $12.12 M 8026 Disposed 2023-12-11 Common Stock (8026) Direct

Footnotes

F1: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017.

F2: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 8, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

F3: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the July 27, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.

F4: Fully vested and exercisable.